Sepsis Therapeutics

Global Market Trajectory & Analytics

MCP-6525

EXECUTIVE ENGAGEMENTS

POOL

798
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

162
Interactions with Platform & by Email

PARTICIPANTS

32
Unique # Participated

VALIDATIONS

13
Responses Validated*

COMPANIES

24
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

18

PAGES

72

EDITION

18

PRICE

USD 5600

CODE

MCP-6525


COMPETITIVE METRICS

COMPANY

D S N T

% *

Adrenomed AG

Login Required

AMOMED Pharma GmbH

Login Required

AM-Pharma BV

Login Required

Arch Biopartners, Inc.

Login Required

Aridis Pharmaceuticals, Inc.

Login Required

Asahi Kasei Pharma America

Login Required

Astellas Pharma, Inc.

Login Required

Biocartis NV

Login Required

Biosyn Arzneimittel GmbH

Login Required

Bristol-Myers Squibb Company

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 24 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Sepsis Therapeutics estimated at US$14.8 Million in the year 2020, is projected to reach a revised size of US$765 Million by 2027, growing at a CAGR of 75.7% over the period 2020-2027.
The Sepsis Therapeutics market in the U.S. is estimated at US$4.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$116.6 Million by the year 2027 trailing a CAGR of 71.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 67.9% and 64.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 51.3% CAGR.

SELECT PLAYERS

Adrenomed AG; AM-Pharma B.V.; Aridis Pharmaceuticals Inc.; Asahi Kasei Pharma America; Astellas Pharma Inc.; Endacea Inc.; InflaRx GmbH; La Jolla Pharmaceutical Company; Opsonix, Inc.; T2 Biosystems Inc.; TaiRx Inc.

SEGMENTS

» Segment (Sepsis Therapeutics)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Sepsis - A Prelude
Recent Market Activity
New Treatment Protocols and New Definitions - Every Minute Counts!!
Aging Population: A Key Growth Driver for Sepsis Therapeutics
Antibiotics and Vasopressors - The Current Standard of Care
Current Categories of Antibacterial Agents for First-line Sepsis Treatment
Current Anti-bacterial Drugs used in Sepsis
Current Antifungals used for Sepsis
Current Antivirals used for Sepsis
GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
Argipressin Gains Approval for Septic Shock in 26 EU countries
Current & Future Analysis
Growth Drivers in a Nutshell
Market Restraints
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Adrenomed AG (Germany)
AM-Pharma B.V. (Netherlands)
AMOMED Pharma GmbH (Austria)
Asahi Kasei Pharma America (USA)
Endacea, Inc. (USA)
InflaRx N.V. (Germany)
La Jolla Pharmaceutical Company (USA)
TaiRx, Inc. (USA)
3. MARKET TRENDS & DRIVERS
A Market Characterized by High Unmet Medical Needs
Research Activity Enables Increased Awareness of Disease Pathogenesis
Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018
Select Sepsis Therapeutics under Phase III Clinical Trials: 2018
Novel Immune-Specific Modes of Action under Focus
Emphasizing on Endothelial Cell Function
HMGB1 - A Potential Target for Future Therapies
Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management
Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients
Hydrocortisone Displays Potential in Septic Shock Treatment
Reduced Levels of Vitamin C Characterize Sepsis Patients
Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models
World Sepsis Day Aims to Result in Improvement in Sepsis Management
NSAIDs Demonstrate Potential to Treat Sepsis
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
CANADA
Canada Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
JAPAN
Japan Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
CHINA
China Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
EUROPE
Europe Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
FRANCE
France Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
GERMANY
Germany Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
ITALY
Italy Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Total Companies Profiled: 24

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com